A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With REGN2810 in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With REGN2810 in Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Isatuximab (Primary) ; REGN 2810 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Sep 2019 to 8 Oct 2019.
    • 10 Aug 2017 Planned primary completion date changed from 1 Sep 2019 to 8 Oct 2019.
    • 10 Aug 2017 Planned initiation date changed from 28 Jul 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top